BPS 2016 Proceedings
Young Investigator Award Speaker
The award was established by the Boulder Peptide Society to recognize and support promising academic researchers in the peptide field who have completed an doctorate degree and are pre-tenure or on a non-tenure track.
Albert Bowers
Professor
University of North Carolina at Chapel Hill
Chemoenzymatic Platforms for the Discovery of New Peptide Therapeutics
Showcase
Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Deborah O’Neil
CEO/CSO
NovaBiotics Ltd
Novamycin, a novel peptide antifungal intervention for clinically challenging mycoses in immunocompromised patients
Jan Johansson
CEO and Founder
ARTERY Therapeutics, Inc.
Cogpep in the treatment of apoE4 associated Alzheimer’s disease
Jesse Z. Dong
Vice President, Peptide Chemistry
Neon Therapeutics
Development of Peptide-Based Personalized Cancer Vaccines
Dana Ault-Riche
CEO
Reflexion Pharmaceuticals
D-amino acid proteins as a new class of pharmaceutical products
Craig Beattie
CSO
CDG Therapeutics Inc
p28, a Non-toxic, Orphan/Rare Pediatric Disease Designated, Cell Penetrating Peptide for the Treatment of Pediatric Brain Tumors
Jonathan Ryves
Chief Executive Officer
Cupid Peptides
Carrying large molecules into the cytosol of living cells with Cupid, a novel cell penetrating peptide
Len Luyt
Associate Professor
University of Western Ontario
The Discovery of Peptides Targeting RHAMM-HA Interactions
Parth Patwari
CSO
ProteoThera, Inc.
Matrix-binding Peptides for Targeted Delivery to Tissues
Scott Peterson
Executive Director, Business Development
Intarcia Therapeutics
Delivering Sustained Release of Peptide Therapeutics via a Subcutaneous Osmotic Mini-Pump
Vinay Singh
Founder & CEO
SYNG Pharmaceuticals Inc
SP011: A First Non-Hormonal Peptide Drug Candidate For Endometriosis
Peptides In the Clinic
Updates on clinical development of peptide therapeutics.
Stephen O’Connor
Senior Director, Chemistry Research and CMC
Cara Therapeutics, Inc.
CR845, A Novel Peripherally Acting Kappa Opioid Receptor Agonist for the Treatment of Pain and Pruritus
Aaron Almeida
Senior Scientist II
Arrowhead Pharmaceuticals
Dynamic PolyConjugates for targeted in vivo delivery of siRNA
James Gilligan
Chief Scientific Officer
Tarsa Therapeutics
Product Development of TBRIAâ„¢, the first oral salmon calcitonin product for the treatment and prevention of post-menopausal osteoporosis
Carolina Vega
Director of Pharmaceutical Development
Apellis Pharmaceuticals
APL-2 and complement inhibition; a potential treatment of PNH and other complement complement-mediated diseases
Lex Van der Ploeg
CSO
Rhythm Pharmaceuticals
Setmelanotide for the treatment of rare forms of monogenic obesity
Jesper Lau
vice president
Novo Nordisk A/S
Design of Long-acting GLP-1 Analogs Applicable for Once Weekly and Oral Dosing
Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies
Robin Polt
Professor of Chemistry & Biochemistry, BIO5
The University of Arizona
Biousian Glycopeptides Penetrate the BBB to Function as CNS Drugs
Weijun Shen
Principal Investigator
California Institute for Biomedical Research
A Peptide Engineering Platform for Generating Stapled Long-acting Peptide Hormones
Adam Mezo
Sr. Research Advisor, Group Leader
Eli Lilly and Company
Comparison of select peptide time-extension technologies in the context of a GIP/GLP-1-based dual-agonist peptide
Danny Chou
Assistant Professor
University of Utah
Bio-inspired protein engineering for ultrafast-acting insulin
Advances in Chemistry
Fa Liu
Director of Chemistry
Novo Nordisk
Novel Synthetic Strategies for Insulin and Related Peptides
Greg Czyryca
President
Allosterix Pharmaceuticals, LLC
Synthetic Biochemistry – Peptides via De Novo Design. Case Study – Modulation of HIV Envelope Protein gp120.
Jean Chmielewski
Distinguished Professor of Chemistry
Purdue University
Targeting Intracellular Pathogenic Bacteria with Unnatural Proline-Rich Peptides: Coupling Antibacterial Activity with Macrophage Penetration
Thomas Tolbert
Associate Professor
The University of Kansas
Synthesis and bioactivity of glycopeptides and peptide-protein conjugates
Chris Holmes
CMC Consultant
Independent Consultant
Setting specification for synthetic peptides
Michael Stowell
CTO
AmideBio
Rapid-Recombinant SAR of Conformation Locked Insulin Analogs